Is Semax legal now? The FDA panel said yes, and rejected a peptide for the first time

What the FDA panel voted on, day two

The Pharmacy Compounding Advisory Committee closed out its two-day hearing on July 24, 2026, taking up the last three of seven peptides under review for the 503A Bulk Drug Substances List, the list that lets licensed compounding pharmacies fill a physician-written prescription under formal FDA recognition. We covered the first day's results when BPC-157, KPV, TB-500, and MOTS-c all passed. Thursday left three names on the table: Semax, Epitalon, and Emideltide.

Semax passed 8-5. Epitalon passed 7-4. Emideltide did not pass, falling 6-7. That makes it the only one of the seven peptides reviewed across the full hearing to get a no from the committee.

Is Semax legal? Not yet, but the panel said yes

Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone, studied in Russia since the 1980s and reviewed here for migraines and other neurological conditions, including cerebral ischemia and trigeminal neuralgia. The committee recommended it for the compounding list by an 8-5 margin, the widest approval margin of the two days after BPC-157 and KPV. Recommended is the operative word. A committee vote is advice to the FDA, not a rule. Semax has never been FDA-approved as a finished drug, and that status has not moved. The question "is Semax legal" still has the same answer it had a week ago: no, though the regulatory path toward compounding access under a physician prescription is now open in a way it was not before Thursday.

Epitalon passed. Our own read did not expect that.

We wrote a full explainer on Epitalon ahead of this hearing and said a reversal looked unlikely, given how thin FDA staff found the record: one small human study that used a sublingual spray and never measured sleep directly, zero human safety data for the injectable route most buyers actually use, and an unresolved concern that epitalon's telomerase-activating effect could raise cancer risk over time rather than lower it. The committee recommended it anyway, 7-4, evaluated for insomnia specifically rather than the anti-aging use most marketing leans on. Worth naming plainly: that prediction was wrong. The pattern across this entire hearing has been a panel voting to recommend compounding access regardless of how weak FDA staff found the underlying evidence, and Epitalon fit that pattern rather than breaking from it.

Why Emideltide failed where six others passed

Emideltide, also sold as DSIP for delta sleep-inducing peptide, was reviewed for opioid withdrawal, insomnia, and narcolepsy. It failed 6-7, a margin thin enough that a single vote decided it. STAT News reported that David Pope, chief pharmacy officer at XiFin Pharmacy Solutions, had voted yes on every peptide taken up the day before, BPC-157, KPV, TB-500, and MOTS-c included, then voted no on Emideltide specifically, citing concern about potentially dangerous downstream consequences. One panelist who had otherwise sided with the majority all week broke from it once, and that was the difference between a sixth approval and the hearing's only rejection.

FDA staff's own June 30 briefing documents had recommended against all seven peptides under review, citing a common set of problems: inconsistent naming and characterization between free base and acetate salt forms, thin or absent human clinical data, and specific safety flags for individual substances. Those documents did not distinguish Emideltide as weaker than the others in any way that obviously predicted this outcome. What changed was not the evidence. It was one vote.

The full scoreboard: two days, seven peptides, one no

Put together, the two-day hearing produced this record. July 23: BPC-157 passed 8-6 with one abstention, KPV passed by the identical margin, and TB-500 and MOTS-c both passed the same afternoon. July 24: Semax passed 8-5, Epitalon passed 7-4, and Emideltide failed 6-7. FDA staff had recommended against every single one of the seven. The committee agreed with staff exactly once, on Emideltide, and disagreed on the other six.

We flagged reporting on conflicts of interest among several newly appointed committee members before this hearing started, and confirmed after day one that those members voted as a bloc on every peptide taken up that day. Emideltide is the first crack in that pattern, and it took only one of them changing his vote to produce it. Whether that reflects a genuine safety line this panel is willing to hold, or simply one panelist's independent judgment on one substance, is not something Thursday's vote by itself can answer.

So what actually changes, and when

For Semax and Epitalon, nothing changes this week. The committee's recommendation now goes to the FDA, which can adopt it, modify it, or reject it outright. If the agency moves forward, the next step is a formal notice-and-comment rulemaking to add each peptide to the 503A Bulks List, a process that includes its own public comment period and carries no statutory deadline. Only after a final rule would a licensed compounding pharmacy be able to fill a physician-written prescription for either peptide under formal FDA authorization. Neither Semax nor Epitalon has ever been FDA-approved as a finished drug, and this vote does not change that either.

For Emideltide, the rejection means the FDA is unlikely to add it to the Bulks List through this nomination cycle, though the agency retains the same discretion to revisit any of the seven peptides later. None of this touches the online research-chemical market that most buyers of any of these peptides use today, which sits outside the compounding system entirely regardless of which way the FDA ultimately rules. For where these peptides fit into a broader stack, see our peptide stacks guide.